Contribute Try STAT+ Today

Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a private-label version up to 75% off the cash price of brand-name analog insulins in a bid to “improve access and lower the cost of care.” But the move was met with a mix of derision and skepticism.

The retailer announced it will sell rapid-acting analog insulin, which is a genetically modified form of human insulin, at $72.88 for a vial and $85.88 for a box of injectable pens. By doing so, the company maintained that anyone who pays cash will be able to save up to $101 off a brand-name vial or $251 off a package of five pens.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment